GlassScriptPhysician profile
Derek Anthony Pride
NPI 1952938847
$1,007.20
in general payments reported to CMS, 2019-2025
12 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $522 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.99 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Ucb, INC. | $242.16 | 2023-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $153.52 | 2023-2025 | |
| Amgen INC. | $133.56 | 2024-2025 | Tepezza, Otezla, Repatha |
| Horizon Therapeutics Plc | $43.55 | 2023 | Krystexxa |
| Averitas Pharma INC. | $34.52 | 2025 | Qutenza |
| Recordati_rare_diseases_inc. | $28.50 | 2025 | Isturisa |
| Radius Health, INC. | $27.80 | 2023-2025 | Tymlos |
| Axsome Therapeutics, INC. | $16.23 | 2024 | Auvelity |
| Lilly USA, LLC | $14.98 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $14.31 | 2024 | Farxiga |
| Boston Scientific Corporation | $14.08 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.